China’s NHSA Introduces Tiered Pricing for COVID-19 Therapies: A, B, and C Categories
The National Healthcare Security Administration (NHSA) has issued a Notification concerning the improvement of the...
Shanghai Pharmaceuticals’ SPH4336 Earns Orphan Drug Status for Liposarcoma Treatment
Shanghai Pharmaceuticals, a leading pharmaceutical company based in China (HKG: 2607, SHA: 601607), has announced...
Junshi Biosciences and Rxilient Biotech Form JV to Commercialize Tuoyi in Southeast Asia
China-based biopharmaceutical company Junshi Biosciences (HKG: 1877, SHA: 688180) has announced a joint venture (JV)...
Novartis’ Kisqali Demonstrates Improved iDFS in Phase III NATALEE Study for Early Breast Cancer
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced that the multi-center, randomized, open-label Phase III...
Keymed Biosciences’ CM310 Achieves Primary Endpoints in Phase III Atopic Dermatitis Study
China-based Keymed Biosciences Inc., a prominent player in the biopharmaceutical industry (HKG: 2162), has announced...
Broncus Medical and Venus Medtech Establish Joint Venture Fund for Digital Medical Equipment
Broncus Medical Inc., (HKG: 2216) a leading provider of lung disease precision intervention solutions based...
AstraZeneca Plans Tripled R&D Investment in China, Aims for 15 New Drugs by 2030
At the AstraZeneca’s (AZ, NASDAQ: AZN) R&D China Science Day, Yicai Global reported that the...
Burning Rock Reports Q4 2022 Revenue Dip but 10.9% Full-Year Growth
Guangzhou-based medical device company Burning Rock (NASDAQ: BNR) has released its financial results for the...
CDE Grants Priority Review Status to TQB3454, HLX208, and Infigratinib for Cancer Treatments
The Center for Drug Evaluation (CDE) website has indicated that Chia Tai Tianqing’s TQB3454, Henlius...
Brii Biosciences Halts Development of Antibody Cocktail for COVID-19 Treatment
Brii Biosciences has announced a strategic decision to end the manufacturing and further development of...
Berry Genomics Partners with MGI Tech to Advance Cancer Diagnostics and Screening
Chengdu-based Berry Genomics Co., Ltd has announced a strategic partnership with MGI Tech, a subsidiary...
PharmaBlock Expands US Presence with New R&D Facility in West Chester
PharmaBlock, a leading company based in Nanjing (SHE: 300725), has announced the opening of a...
CSPC Pharmaceutical Receives NMPA Approval for Generic Otezla Equivalent
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that its generic version of Celgene’s...
NMPA Introduces Procedures to Adjust Chemical Generic Reference Preparations
The National Medical Products Administration (NMPA) has released a document outlining procedures for the adjustment...
BJ Bioscience Partners with MSD for Phase I Clinical Trial of BJ-001 and Keytruda
Shanghai-based biotech BJ Bioscience Inc. has announced a clinical trial collaboration and supply agreement with...
Acotec Scientific’s Vericor Receives Marketing Approval from Thailand FDA
China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced that it has received marketing approval...
CANbridge Pharmaceuticals Completes Enrollment in Phase II GBM Trial for CAN008
Sino-US biopharma CANbridge Pharmaceuticals (HKG: 1228) has announced the completion of patient enrollment in a...
Chongqing Genrix’s Xeligekimab for Psoriasis Accepted for Market Approval Review
China-based Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443) has announced that the market approval filing...
Hansoh Pharmaceutical Reports 2022 Revenues and Highlights Growth in Innovative Drugs
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has released its financial report for 2022....
National ADR Monitoring Report Highlights Oncology Drugs and Elderly Patient Safety
The National Center for ADR Monitoring has published its “National Adverse Drug Reaction Monitoring Annual...